Dataset Information


Celecoxib extends C. elegans lifespan via inhibition of insulin-like signaling but not cyclooxygenase-2 activity.

ABSTRACT: One goal of aging research is to develop interventions that combat age-related illnesses and slow aging. Although numerous mutations have been shown to achieve this in various model organisms, only a handful of chemicals have been identified to slow aging. Here, we report that celecoxib, a nonsteroidal anti-inflammatory drug widely used to treat pain and inflammation, extends Caenorhabditis elegans lifespan and delays the age-associated physiological changes, such as motor activity decline. Celecoxib also delays the progression of age-related proteotoxicity as well as tumor growth in C. elegans. Celecoxib was originally developed as a potent cyclooxygenase-2 (COX-2) inhibitor. However, the result from a structural-activity analysis demonstrated that the antiaging effect of celecoxib might be independent of its COX-2 inhibitory activity, as analogs of celecoxib that lack COX-2 inhibitory activity produce a similar effect on lifespan. Furthermore, we found that celecoxib acts directly on 3'-phosphoinositide-dependent kinase-1, a component of the insulin/IGF-1 signaling cascade to increase lifespan.


PROVIDER: S-EPMC3094508 | BioStudies | 2011-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6612998 | BioStudies
2014-01-01 | S-EPMC4063773 | BioStudies
1000-01-01 | S-EPMC4637296 | BioStudies
2020-01-01 | S-EPMC7378611 | BioStudies
2020-01-01 | S-EPMC7138547 | BioStudies
2019-01-01 | S-EPMC6657616 | BioStudies
1000-01-01 | S-EPMC4311797 | BioStudies
2015-01-01 | S-EPMC4567989 | BioStudies
1000-01-01 | S-EPMC1821127 | BioStudies
1000-01-01 | S-EPMC6052467 | BioStudies